1. Home
  2. PLSE vs AUPH Comparison

PLSE vs AUPH Comparison

Compare PLSE & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PLSE
  • AUPH
  • Stock Information
  • Founded
  • PLSE 2014
  • AUPH 1993
  • Country
  • PLSE United States
  • AUPH Canada
  • Employees
  • PLSE N/A
  • AUPH N/A
  • Industry
  • PLSE Medical/Dental Instruments
  • AUPH Biotechnology: Pharmaceutical Preparations
  • Sector
  • PLSE Health Care
  • AUPH Health Care
  • Exchange
  • PLSE Nasdaq
  • AUPH Nasdaq
  • Market Cap
  • PLSE 1.1B
  • AUPH 1.4B
  • IPO Year
  • PLSE 2016
  • AUPH 1999
  • Fundamental
  • Price
  • PLSE $16.27
  • AUPH $12.30
  • Analyst Decision
  • PLSE Buy
  • AUPH Strong Buy
  • Analyst Count
  • PLSE 1
  • AUPH 3
  • Target Price
  • PLSE $22.00
  • AUPH $12.00
  • AVG Volume (30 Days)
  • PLSE 178.1K
  • AUPH 1.5M
  • Earning Date
  • PLSE 10-29-2025
  • AUPH 11-06-2025
  • Dividend Yield
  • PLSE N/A
  • AUPH N/A
  • EPS Growth
  • PLSE N/A
  • AUPH N/A
  • EPS
  • PLSE N/A
  • AUPH 0.42
  • Revenue
  • PLSE N/A
  • AUPH $260,111,000.00
  • Revenue This Year
  • PLSE N/A
  • AUPH $16.92
  • Revenue Next Year
  • PLSE $700.00
  • AUPH $14.43
  • P/E Ratio
  • PLSE N/A
  • AUPH $29.12
  • Revenue Growth
  • PLSE N/A
  • AUPH 25.59
  • 52 Week Low
  • PLSE $13.77
  • AUPH $6.55
  • 52 Week High
  • PLSE $25.00
  • AUPH $12.90
  • Technical
  • Relative Strength Index (RSI)
  • PLSE 56.35
  • AUPH 56.77
  • Support Level
  • PLSE $13.83
  • AUPH $12.06
  • Resistance Level
  • PLSE $16.80
  • AUPH $12.90
  • Average True Range (ATR)
  • PLSE 0.73
  • AUPH 0.39
  • MACD
  • PLSE 0.10
  • AUPH -0.08
  • Stochastic Oscillator
  • PLSE 82.15
  • AUPH 54.89

About PLSE Pulse Biosciences Inc (DE)

Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed-Field Ablation or nsPFA technology when used to ablate cellular tissue, can be used to treat a variety of medical conditions for which an optimal solution remains unfulfilled.

About AUPH Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.

Share on Social Networks: